London
25 °C
Manchester
21 °C
Glasgow
Dublin
20 °C
Belfast
Washington
Denver
Atlanta
Dallas
29 °C
Houston Texas
New Orleans
27 °C
El Paso
Phoenix
Los Angeles
24 °C
20 °C
7 °C
16 °C
12 °C
25 °C
Johnson & Johnson temporarily halts Covid-19 vaccine output: report / Photo: ©
NYSE - LSE
| RBGPF | -5.79% | 71.84 | $ | |
| RYCEF | 0.07% | 14.46 | $ | |
| CMSC | 0.43% | 23.06 | $ | |
| VOD | 1.01% | 11.375 | $ | |
| BCC | -0.2% | 83.02 | $ | |
| GSK | 0.83% | 37.895 | $ | |
| RIO | 1.92% | 61.96 | $ | |
| AZN | -0.76% | 73.495 | $ | |
| SCS | 0.06% | 16.01 | $ | |
| SCU | 0% | 12.72 | $ | |
| JRI | -0.04% | 13.405 | $ | |
| NGG | -1.04% | 71.335 | $ | |
| RELX | -1.76% | 48.21 | $ | |
| CMSD | -0.13% | 23.49 | $ | |
| BTI | 0.6% | 57.035 | $ | |
| BCE | 2.52% | 24.395 | $ | |
| BP | 0.06% | 34.21 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
Y.Gomez--SFF
